2,4-二溴-6-(三氟甲基)苯酚 | 392-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二溴-6-(三氟甲基)苯酚
• 英文名称: 2,4-dibromo-6-trifluoromethyl-phenol
• 英文别名: α.α.α-Trifluor-3.5-dibrom-2-hydroxy-toluol；3.5-Dibrom-2-hydroxy-1-trifluormethyl-benzol；2,4-Dibrom-6-trifluormethyl-phenol；2,4-dibromo-6-trifluoromethylphenol；4,6-Dibrom-2-trifluormethylphenol；2,4-Dibromo-6-(trifluoromethyl)phenol
• CAS: 392-92-7
• 化学式: C₇H₃Br₂F₃O
• 分子量: 319.903
• InChiKey: DJPAQOCIUDXBHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2908199090

反应信息

• 作为反应物：
  描述：

  2,4-二溴-6-(三氟甲基)苯酚 在 sodium hydroxide 作用下， 生成 3,5-二溴-2-羟基苯甲酸
  参考文献：
  名称：

  Jones, Journal of the American Chemical Society, 1947, vol. 69, p. 2352

  摘要：

  DOI：
• 作为产物：
  描述：

  2-硝基-Alpha,Alpha,Alpha-三氟甲苯 在 水 、 溴 、 钯 作用下， 生成 2,4-二溴-6-(三氟甲基)苯酚
  参考文献：
  名称：

  Jones, Journal of the American Chemical Society, 1947, vol. 69, p. 2352

  摘要：

  DOI：

文献信息

• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟
• Process for the preparation of certain substituted aromatic compounds
  申请人：Norwich Eaton Pharmaceuticals, Inc.

  公开号：US04982006A1

  公开（公告）日：1991-01-01

  The present invention involves process for the preparation of compounds having the chemical structure: ##STR1## wherein Ar--H is an aromatic compound which is activated to an electrophilic attack, and wherein --Y is an aliphatic group having a labile moiety, especially where the labile moiety is a terminally unsaturated moiety: --C.tbd.CH, ##STR2## or aldehydes in the form of their acetals. The process comprises the step of reacting Ar--H and ##STR3## wherein --X is --Cl or --Br, and where the reaction step is carried out in a solvent medium at a temperature of from about -40.degree. C. to about -100.degree. C. using stannic chloride as a catalyst.

  该发明涉及一种制备具有以下化学结构的化合物的过程：其中Ar-H是被激活以进行亲电攻击的芳香族化合物，而--Y是具有易失性基团的脂肪族基团，特别是易失性基团是末端不饱和基团：--C.tbd.CH，或者以他们的缩醛的形式。该过程包括反应Ar-H和其中--X是--Cl或--Br的反应步骤，在溶剂介质中在约-40摄氏度至约-100摄氏度的温度下使用氯化锡作为催化剂进行反应。
• Novel Phosphorus-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20100081634A1

  公开（公告）日：2010-04-01

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有膦酸的T3模拟物化合物及其单酯、立体异构体、药学上可接受的盐、共晶体和前药及其药学上可接受的盐和共晶体，以及它们的制备和用于预防和/或治疗代谢性疾病，如肥胖症、NASH、高胆固醇血症和高脂血症，以及相关疾病，如动脉粥样硬化、冠心病、糖耐量受损、代谢综合征X和糖尿病的用途。
• Novel phosphorus-containing thyromimetics
  申请人：Erion D. Mark

  公开号：US20060046980A1

  公开（公告）日：2006-03-02

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有膦酸基的T3类似物化合物及其单酯体、立体异构体、药学上可接受的盐、共晶体和其前药物，以及前药物的药学上可接受的盐和共晶体，以及它们的制备和用于预防和/或治疗代谢性疾病，如肥胖症、NASH、高胆固醇血症和高脂血症，以及相关疾病，如动脉粥样硬化、冠心病、糖耐量受损、代谢综合征x和糖尿病。
• Thiazole Derivatives as CXCR3 Receptor Modulators
  申请人：Adams Alan D.

  公开号：US20090143413A1

  公开（公告）日：2009-06-04

  The invention encompasses compounds of Formula I (I) or pharmaceutically acceptable salts thereof, which are antagonist of the CXCR3 chemokine receptor useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

  该发明涵盖公式I（I）的化合物或其药学上可接受的盐，它们是CXCR3趋化因子受体的拮抗剂，可用于治疗或预防病原体引起的炎症过程、自身免疫性疾病或移植排斥过程。还涵盖使用方法和制药组合物。